Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes

PHASE3CompletedINTERVENTIONAL
Enrollment

1,801

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

August 28, 2022

Study Completion Date

August 28, 2022

Conditions
Acute Coronary Syndrome
Interventions
BIOLOGICAL

Double Dose Quadrivalent Influenza Vaccine

Double Dose QIV (30µg Hemagglutinin)

BIOLOGICAL

Standard Dose Quadrivalent Influenza Vaccine

Standard Dose QIV (15µg Hemagglutinin)

Trial Locations (22)

Unknown

Universidade Federal do Ceará / Hospital Universitário Walter Cantídio, Fortaleza

Hospital e Clínica São Roque, Ipiaú

Hospital Ana Nery, Salvador

Hospital Cárdio Pulmonar, Salvador

Instituto de Cardiologia do Distrito Federal, Brasília

Hospital Universitário Ciências Médicas, Belo Horizonte

Hospital Santa Lucia, Poços de Caldas

Hospital Universitario da Universidade Estadual de Londrina, Londrina

Hospital Agamenon Magalhães, Recife

Pronto Socorro Cardiológico de Pernambuco, Recife

Instituto Estadual de Cardiologia Aloysio de Castro, Rio de Janeiro

Hospital de Clínicas de Porto Alegre, Porto Alegre

Hospital São Lucas da PUCRS, Porto Alegre

IPEMI - Instituto de Pesquisas Médicas de Itajaí, Itajaí

Hospital Dona Helena, Joinville

Hospital Regional Hans Dieter Schmidt, Joinville

Centro de Pesquisa Clinica do Coração, Aracaju

Faculdade de Medicina de Botucatu - UNESP, Botucatu

Irmandade da Santa Casa de Misericórdia de Marília, Marília

Santa Casa de Misericórdia de Presidente Prudente, Presidente Prudente

Instituto do Coração - HC FMUSP, São Paulo

Instituto Dante Pazzanese, São Paulo

All Listed Sponsors
collaborator

Ministry of Health, Brazil

OTHER_GOV

lead

Hospital Israelita Albert Einstein

OTHER

NCT04001504 - Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes | Biotech Hunter | Biotech Hunter